Prostate Cancer Clinical Trials in Los Angeles, California

28 studies are recruiting for prostate cancer in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

    The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally adv…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Los Angeles, California
    Locations
    346 in total
    Run by
    AstraZeneca

    See if you can join NCT06952803 on ClinicalTrials.gov

  2. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Cedars-Sinai Medical Center ( Site 0068), Los Angeles, California
    Locations
    298 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06925737 on ClinicalTrials.gov

  3. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  4. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

    The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Urology Group of Southern California, Los Angeles, California
    Locations
    34 in total
    Run by
    Clarity Pharmaceuticals Ltd

    See if you can join NCT06056830 on ClinicalTrials.gov

  5. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

    AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    USC/Norris Comprehensive Cancer Center, Los Angeles, California
    Locations
    7 in total
    Run by
    Angiex, Inc.

    See if you can join NCT06440005 on ClinicalTrials.gov

  6. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California
    Locations
    39 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

  7. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Southern California, Los Angeles, California
    Locations
    10 in total
    Run by
    Nammi Therapeutics Inc

    See if you can join NCT06582017 on ClinicalTrials.gov

  8. Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

    This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study i…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    START Los Angeles, Los Angeles, California
    Locations
    14 in total
    Run by
    Monte Rosa Therapeutics, Inc

    See if you can join NCT07745361 on ClinicalTrials.gov

  9. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California, Los Angeles (UCLA), Los Angeles, California
    Locations
    33 in total
    Run by
    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

  10. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

    This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles, California
    Locations
    337 in total
    Run by
    Pfizer

    See if you can join NCT07028853 on ClinicalTrials.gov

  11. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    USC Norris Comprehensive Cancer Center, Los Angeles, California
    Locations
    36 in total
    Run by
    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

  12. NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making

    In this pilot study, the investigators will show feasibility of the NLP-based feedback system in 20 consultations of men with newly diagnosed prostate cancer. The investigators will recruit from the practices of up to 10 physicians who typically see these patients. The investigators will report the…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Cedars-Sinai Medical Center, Los Angeles, California
    Run by
    Cedars-Sinai Medical Center

    See if you can join NCT05923684 on ClinicalTrials.gov

  13. WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

    This is a randomized control trial testing the effect of walnut supplementation on prostate cancer progression in 50 men with biopsy confirmed prostate cancer and planning to undergo RP. Patients consented to the study will be randomly assigned to either continue their usual diets (control arm) or …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Cedars-Sinai Medical Center, Los Angeles, California
    Run by
    Stephen Freedland

    See if you can join NCT03824652 on ClinicalTrials.gov

  14. A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

    To determine the effects of exercise therapy on molecular, radiologic, and pathologic nimbosus hallmarks versus usual care control in men on Active Surveillance for localized prostate cancer.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of California, Los Angeles (Data and Specimen Analysis Only), Los Angeles, California
    Locations
    10 in total
    Run by
    City of Hope Medical Center

    See if you can join NCT05751434 on ClinicalTrials.gov

  15. PSMA PET Combined With MRI for the Detection of PCa

    This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of California Los Angeles, Los Angeles, California
    Locations
    18 in total
    Run by
    Telix Pharmaceuticals (Innovations) Pty Limited

    See if you can join NCT07052214 on ClinicalTrials.gov

  16. Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

    The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Start Lacn, Los Angeles, California
    Locations
    3 in total
    Run by
    Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

    See if you can join NCT07517198 on ClinicalTrials.gov

  17. Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

    This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy. Treatment of interest: the investigational tre…

    Stage
    Phase 2
    Ages
    18 to 100
    Site
    VA Greater LA Healthcare System, Los Angeles, California
    Locations
    81 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT06780670 on ClinicalTrials.gov

  18. Active Surveillance for Cancer of the Prostate (ASCaP)

    Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progres…

    Stage
    Not phased
    Ages
    30 to 85
    Site
    University of California Los Angeles, Los Angeles, California
    Run by
    Jonsson Comprehensive Cancer Center

    See if you can join NCT00949819 on ClinicalTrials.gov

  19. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

    Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

    Stage
    Not phased
    Ages
    21 and older
    Site
    University of California - Los Angeles, Los Angeles, California
    Locations
    121 in total
    Run by
    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT03151629 on ClinicalTrials.gov

  20. Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

    This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.

    Stage
    Not phased
    Ages
    18 and older
    Site
    UCLA, Los Angeles, California
    Locations
    4 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT05948657 on ClinicalTrials.gov

  21. HIFU for Focal Ablation of Prostate Tissue: An Observational Study

    The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnair…

    Stage
    Not phased
    Ages
    40 to 85
    Site
    University of California, Los Angeles, Los Angeles, California
    Run by
    University of California, Los Angeles

    See if you can join NCT03620786 on ClinicalTrials.gov

  22. Mechanisms of Resistance to PSMA Radioligand Therapy

    This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of California, Los Angeles, Los Angeles, California
    Locations
    3 in total
    Run by
    University of California, San Francisco

    See if you can join NCT05435495 on ClinicalTrials.gov

  23. Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

    To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate cancer patients who are in active surveillance and undergoing a planned surveillance biopsy in 3-6 …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Cedars-Sinai Medical Center, Los Angeles, California
    Run by
    Cedars-Sinai Medical Center

    See if you can join NCT06437574 on ClinicalTrials.gov

  24. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    USC - Norris Comprehensive Cancer Center, Los Angeles, California
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  25. Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment

    With people living longer after being treated for prostate cancer, quality of life has become a concern when considering the treatment plan. Sometimes after radiation therapy, patients may experience problems that affect the urinary and bowel systems, along with sexual function. Stereotactic body r…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of California at Los Angeles, Los Angeles, California
    Run by
    Jonsson Comprehensive Cancer Center

    See if you can join NCT07293585 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.